37 results on '"Blanke, Philipp"'
Search Results
2. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation
- Author
-
Ruile, Philipp, Jander, Nikolaus, Blanke, Philipp, Schoechlin, Simon, Reinöhl, Jochen, Gick, Michael, Rothe, Juergen, Langer, Mathias, Leipsic, Jonathon, Buettner, Heinz-Joachim, Neumann, Franz-Josef, and Pache, Gregor
- Published
- 2017
- Full Text
- View/download PDF
3. Role of MDCT Imaging in Planning Mitral Valve Intervention
- Author
-
Grover, Rominder, Ohana, Mickael, Arepalli, Chesnal Dey, Sellers, Stephanie L., Mooney, John, Kueh, Shaw-Hua, Kim, Ung, Blanke, Philipp, and Leipsic, Jonathon A.
- Published
- 2018
- Full Text
- View/download PDF
4. Transcatheter Aortic Valve Replacement Planning with Cardiac CT: Protocols and Practical Tips
- Author
-
Soon, Jeanette, Naoum, Christopher, Blanke, Philipp, and Leipsic, Jonathon
- Published
- 2016
- Full Text
- View/download PDF
5. Clinical and Echocardiographic Characteristics of Flow-Based Classification Following Balloon-Expandable Transcatheter Heart Valve in PARTNER Trials.
- Author
-
Akinmolayemi, Oludamilola, Ozdemir, Denizhan, Pibarot, Philippe, Zhao, Yanglu, Leipsic, Jonathon, Douglas, Pamela S., Jaber, Wael A., Weissman, Neil J., Blanke, Philipp, and Hahn, Rebecca T.
- Abstract
Current expected normal echocardiographic measures of transcatheter heart valve (THV) function were derived from pooled cohorts of the randomized trials; however, THV function by flow state before or following transcatheter aortic valve replacement (TAVR) has not been previously reported. This study sought to assess the expected normal echocardiographic hemodynamics for the balloon-expandable THV grouped by stroke volume index (SVI). Patients with severe aortic stenosis enrolled in PARTNER (Placement of Aortic Transcatheter Valves) 1 (high/extreme surgical risk), PARTNER 2 (intermediate surgical risk), or PARTNER 3 (low surgical risk) trials with complete core laboratory echocardiography were included. Patients were grouped by low-flow (SVI LOW <35 mL/m
2 ) and normal-flow (SVI NORMAL ≥35 mL/m2 ). Mean gradient, effective orifice area (EOA), and Doppler velocity index (DVI) were collected at baseline and at 30 days post-TAVR. Prosthesis-patient mismatch (PPM) was both calculated and predicted from normative data, using defined criteria. In the entire population (N = 4,991), mean age was 81.8 years, 58% of patients were male, and 42% had low flow. Compared with patients with baseline SVI NORMAL , those with SVI LOW were more likely to be male; have more comorbidities; and lower left ventricular ejection fraction, mean gradient, and EOA. Post-TAVR, SVI LOW increased to SVI NORMAL in 17.3% and SVI NORMAL decreased to SVI LOW in 12.3% of patients. Using baseline SVI, follow-up EOA, mean gradient, and DVI for patients with SVI LOW tended to be lower than for patients with SVI NORMAL. Using the post-TAVR SVI, follow-up EOA, mean gradient, and DVI were significantly lower for patients with SVI LOW than for those with SVI NORMAL (P < 0.001 for all). The incidence of calculated, but not predicted, severe PPM was higher in patients with low flow than it was in patients with normal flow, suggesting pseudo-PPM in the presence of low flow. This study demonstrates that flow affects THV hemodynamics and both baseline and follow-up SVI should be considered when predicting THV hemodynamics prior to TAVR, as well as assessing valve function following valve implantation. [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. Annular versus supra-annular sizing for transcatheter aortic valve replacement in bicuspid aortic valve disease
- Author
-
Weir-McCall, Jonathan R, Attinger-Toller, Adrian, Blanke, Philipp, Perlman, Gidon Y, Sellers, Stephanie L, Wood, David, Webb, John G, Leipsic, Jonathon, Weir-McCall, Jonathan [0000-0001-5842-842X], and Apollo - University of Cambridge Repository
- Subjects
Male ,Computer tomography ,Bicuspid aortic valve ,Computed Tomography Angiography ,Heart Valve Diseases ,Coronary Angiography ,Prosthesis Design ,Severity of Illness Index ,Transcatheter Aortic Valve Replacement ,Bicuspid Aortic Valve Disease ,Predictive Value of Tests ,Multidetector Computed Tomography ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Aortic stenosis ,Aortic Valve Stenosis ,Tavr ,Middle Aged ,Valvular disease ,Treatment Outcome ,Echocardiography ,Aortic Valve ,Heart Valve Prosthesis ,Female - Abstract
BACKGROUND: CT measurement of supra-annular area (SA) has been proposed as an alternative to annular area (AA) for sizing of trancatheter valves in biscuspid aortic valves (BAV). This study examines the reproducibility of SA and AA measurements and their potential impact on downstream transcatheter heart valve sizing and clinical outcomes. METHODS: 44 consecutive patients (mean age: 73 ± 15 years, 57% male) undergoing CTA with subsequent SAPIEN 3 valve insertion for severe bicuspid aortic stenosis (AS) were included. AA was measured at the basal ring. SA was measured by generating a circle defined by the intercommisural distance. AA and SA were measured by 2 independent observers. Baseline characteristics, TAVR procedural data, and discharge echocardiography data were collected. RESULTS: The SA was significantly larger than the AA (562 ± 146mm2 vs. 518 ± 112mm2,p = 0.013). Interobserver agreement was high using both techniques (ICC AA = 0.98,p < 0.001; SA = 0.80,p < 0.001), but with narrower limits of agreement with AA measurements (mean difference (limits of agreement): AA = -3mm2 (22; 19), SA = -16mm2 (-92; 76)). AA-based device sizing demonstrated substantial agreement with final valve inserted (κ = 0.72,p < 0.001), while SA demonstrated fair agreement (κ = 0.40,p < 0.001). There was no difference in post TAVR gradients, paravalvular leakage or valve success between patients with concordant sizing between AA and SA, and those in whom SA would have suggested an alternate valve size. CONCLUSIONS: Supra-annular sizing is less reproducible than annular sizing, with no difference in procedural complication rates in patients in whom supra-annular sizing would have altered the device size used. These results suggest no role for supra-annular sizing in current clinical practice.
- Published
- 2020
- Full Text
- View/download PDF
7. Late Balloon Valvuloplasty for Transcatheter Heart Valve Dysfunction.
- Author
-
Akodad, Mariama, Blanke, Philipp, Chuang, Ming-Yu A., Duchscherer, Jade, Sellers, Stephanie L., Chatfield, Andrew G., Gulsin, Gaurav G., Lauck, Sandra, Leipsic, Jonathon A., Meier, David, Moss, Rob R., Cheung, Anson, Sathananthan, Janarthanan, Wood, David A., Ye, Jian, and Webb, John G.
- Subjects
- *
PERCUTANEOUS balloon valvuloplasty , *HEART valves , *HEART valve prosthesis implantation , *AORTIC stenosis , *TREATMENT effectiveness , *PROSTHETIC heart valves , *CATHETERIZATION , *PROSTHESIS design & construction ,AORTIC valve surgery - Abstract
Background: Transcatheter heart valve (THV) dysfunction with an elevated gradient or paravalvular leak (PVL) may be documented late after THV implantation. Medical management, paravalvular plugs, redo THV replacement, or surgical valve replacement may be considered. However, late balloon dilatation is rarely utilized because of concerns about safety or lack of efficacy.Objectives: We aimed to evaluate the safety and efficacy of late dilatation in the management of THV dysfunction.Methods: All patients who underwent late dilatation for symptomatic THV dysfunction at 2 institutions between 2016 and 2021 were identified. Baseline, procedural characteristics, and clinical and echocardiographic outcomes were documented. THV frame expansion was assessed by multislice computed tomography before and after late dilatation.Results: Late dilatation was performed in 30 patients a median of 4.6 months (IQR: 2.3-11.0 months) after THV implantation in the aortic (n = 25; 83.3%), mitral (n = 2; 6.7%), tricuspid (n = 2; 6.7%) and pulmonary (n = 1; 3.3%) position. THV underexpansion was documented at baseline, and frame expansion substantially improved after late dilatation. The mean transvalvular gradient fell in all patients. For aortic THVs specifically, mean transaortic gradient fell from 25.4 ± 13.9 mm Hg to 10.8 ± 4.1 mm Hg; P < 0.001. PVL was reduced to ≤mild in all 11 patients with a previous >mild PVL. Embolic events, stroke, annular injury, and bioprosthetic leaflet injury were not observed. Symptomatic benefit was durable at 19.6 months (IQR: 14.8-36.1 months) follow-up.Conclusions: Balloon dilatation late after THV implantation appears feasible and safe in appropriately selected patients and may result in THV frame expansion resulting in improvements in hemodynamic performance and PVL. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. TAVI in 2022: Remaining issues and future direction.
- Author
-
Webb, John G., Blanke, Philipp, Meier, David, Sathananthan, Janarthanan, Lauck, Sandra, Chatfield, Andrew G., Jelijevas, Julius, Wood, David A., and Akodad, Mariama
- Abstract
Copyright of Archives of Cardiovascular Diseases is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
9. The PARTNER 3 Bicuspid Registry for Transcatheter Aortic Valve Replacement in Low-Surgical-Risk Patients.
- Author
-
Williams, Mathew R., Jilaihawi, Hasan, Makkar, Raj, O'Neill, William W., Guyton, Robert, Malaisrie, S. Chris, Brown, David L., Blanke, Philipp, Leipsic, Jonathon A., Pibarot, Philippe, Hahn, Rebecca T., Leon, Martin B., Cohen, David J., Bax, Jeroen J., Kodali, Susheel K., Mack, Michael J., Lu, Michael, and Webb, John G.
- Abstract
The study compared 1-year outcomes between transcatheter aortic valve replacement (TAVR) patients with bicuspid aortic valve (BAV) morphology and clinically similar patients having tricuspid aortic valve (TAV) morphology. There are limited prospective data on TAVR using the SAPIEN 3 device in low-surgical-risk patients with severe, symptomatic aortic stenosis and bicuspid anatomy. Low-risk, severe aortic stenosis patients with BAV were candidates for the PARTNER 3 (Placement of Aortic Transcatheter Valves 3) (P3) bicuspid registry or the P3 bicuspid continued access protocol. Patients treated in these registries were pooled and propensity score matched to TAV patients from the P3 randomized TAVR trial. Outcomes were compared between groups. The primary endpoint was the 1-year composite rate of death, stroke, and cardiovascular rehospitalization. Of 320 total submitted BAV patients, 169 (53%) were treated, and most were Sievers type 1. The remaining 151 patients were excluded caused by anatomic or clinical criteria. Propensity score matching with the P3 TAVR cohort (496 patients) yielded 148 pairs. There were no differences in baseline clinical characteristics; however, BAV patients had larger annuli and they experienced longer procedure duration. There was no difference in the primary endpoint between BAV and TAV (10.9% vs 10.2%; P = 0.80) or in the rates of the individual components (death: 0.7% vs 1.4%; P = 0.58; stroke: 2.1% vs 2.0%; P = 0.99; cardiovascular rehospitalization: 9.6% vs 9.5%; P = 0.96). Among highly select bicuspid aortic stenosis low-surgical-risk patients without extensive raphe or subannular calcification, TAVR with the SAPIEN 3 valve demonstrated similar outcomes to a matched cohort of patients with tricuspid aortic stenosis. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Impact of Annular Oversizing on Paravalvular Regurgitation and Valve Hemodynamics: New Insights From PARTNER 3.
- Author
-
Ihdayhid, Abdul Rahman, Leipsic, Jonathon, Hahn, Rebecca T., Pibarot, Philippe, Thourani, Vinod, Makkar, Raj, Kodali, Susheel, Russo, Mark, Kapadia, Samir, Chen, Yanjun, Mack, Michael, Webb, John, Bax, Jeroen, Leon, Martin B., and Blanke, Philipp
- Abstract
This study sought to investigate the impact of computed tomography (CT)–based area and perimeter oversizing on the incidence of paravalvular regurgitation (PVR) and valve hemodynamics in patients treated with the SAPIEN 3 transcatheter heart valve (THV). The incremental value of considering annular perimeter or left ventricular outflow tract measurements and the impact of THV oversizing on valve hemodynamics are not well defined. The PARTNER 3 (Placement of Aortic Transcatheter Valves 3) trial included 495 low-surgical-risk patients with severe aortic stenosis who underwent THV implantation. THV sizing was based on annular area assessed by CT. Area- and perimeter-based oversizing was determined using systolic annular CT dimensions and nominal dimensions of the implanted THV. PVR, effective orifice area, and mean gradient were assessed on 30-day transthoracic echocardiography. Of 485 patients with available CT and echocardiography data, mean oversizing was 7.9 ± 8.7% for the annulus area and 2.1 ± 4.1% for the perimeter. A very low incidence of ≥moderate PVR (0.6%) was observed, including patients with minimal annular oversizing. Incidence of ≥mild PVR and need for procedural post-dilatation were inversely related to the degree of oversizing. For patients with annular dimensions suitable for 2 THV sizes, the larger THV with both area and perimeter oversizing was associated with the lowest incidence of ≥mild PVR (12.0% vs 43.4%; P < 0.0001). Left ventricular outflow tract area oversizing was not associated with PVR. THV prosthesis size, rather than degree of oversizing, had greatest impact on effective orifice area and mean gradient. In low-surgical-risk patients, a low incidence of ≥moderate PVR was observed, including patients with minimal THV oversizing. The degree of prosthesis oversizing had the greatest impact on reducing mild PVR and incidence of post-dilatation, without impacting valve hemodynamics. In selected patients with annular dimensions in between 2 valve sizes, the larger THV device oversized to both the annular area and perimeter reduced PVR and optimized THV hemodynamics. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Prosthesis-Patient Mismatch After Aortic Valve Replacement in the PARTNER 2 Trial and Registry.
- Author
-
Ternacle, Julien, Pibarot, Philippe, Herrmann, Howard C., Kodali, Susheel, Leipsic, Jonathon, Blanke, Philipp, Jaber, Wael, Mack, Michael J., Clavel, Marie-Annick, Salaun, Erwan, Guzzetti, Ezequiel, Annabi, Mohamed-Salah, Bernier, Mathieu, Beaudoin, Jonathan, Khalique, Omar K., Weissman, Neil J., Douglas, Pamela, Bax, Jeroen, Dahou, Abdellaziz, and Xu, Ke
- Abstract
This study aimed to compare incidence and impact of measured prosthesis-patient mismatch (PPM M) versus predicted PPM (PPM P) after surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). TAVR studies have used measured effective orifice area indexed (EOAi) to body surface area (BSA) to define PPM, but most SAVR series have used predicted EOAi. This difference may contribute to discrepancies in incidence and outcomes of PPM between series. The study analyzed SAVR patients from the PARTNER (Placement of Aortic Transcatheter Valves) 2A trial and TAVR patients from the PARTNER 2 SAPIEN 3 Intermediate Risk registry. PPM was classified as moderate if EOAi ≤0.85 cm
2 /m2 (≤0.70 if obese: body mass index ≥30 kg/m2 ) and severe if EOAi ≤0.65 cm2 /m2 (≤0.55 if obese). PPM M was determined by the core lab–measured EOAi on 30-day echocardiogram. PPM P was determined by 2 methods: 1) using normal EOA reference values previously reported for each valve model and size (PPM P1 ; n = 929 SAVR, 1,069 TAVR) indexed to BSA; and 2) using normal reference EOA predicted from aortic annulus size measured by computed tomography (PPM P2 ; n = 864 TAVR only) indexed to BSA. Primary endpoint was the composite of 5-year all-cause death and rehospitalization. The incidence of moderate and severe PPM P was much lower than PPM M in both SAVR (PPM P1 : 28.4% and 1.2% vs. PPM M : 31.0% and 23.6%) and TAVR (PPM P1 : 21.0% and 0.1% and PPM P2 : 17.0% and 0% vs. PPM M : 27.9% and 5.7%). The incidence of severe PPM M and severe PPM P1 was lower in TAVR versus SAVR (P < 0.001). The presence of PPM by any method was associated with higher transprosthetic gradient. Severe PPM P1 was independently associated with events in SAVR after adjustment for sex and Society of Thoracic Surgeons score (hazard ratio: 3.18;95% CI: 1.69-5.96; P < 0.001), whereas no association was observed between PPM by any method and outcomes in TAVR. EOAi measured by echocardiography results in a higher incidence of PPM following SAVR or TAVR than PPM based on predicted EOAi. Severe PPM P is rare (<1.5%), but is associated with increased all-cause death and rehospitalization after SAVR, whereas it is absent following TAVR. [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Personalized intervention cardiology with transcatheter aortic valve replacement made possible with a non-invasive monitoring and diagnostic framework.
- Author
-
Khodaei, Seyedvahid, Henstock, Alison, Sadeghi, Reza, Sellers, Stephanie, Blanke, Philipp, Leipsic, Jonathon, Emadi, Ali, and Keshavarz-Motamed, Zahra
- Subjects
HEART valve prosthesis implantation ,AORTIC stenosis ,CARDIOVASCULAR diseases ,BLOOD flow ,HEART function tests - Abstract
One of the most common acute and chronic cardiovascular disease conditions is aortic stenosis, a disease in which the aortic valve is damaged and can no longer function properly. Moreover, aortic stenosis commonly exists in combination with other conditions causing so many patients suffer from the most general and fundamentally challenging condition: complex valvular, ventricular and vascular disease (C3VD). Transcatheter aortic valve replacement (TAVR) is a new less invasive intervention and is a growing alternative for patients with aortic stenosis. Although blood flow quantification is critical for accurate and early diagnosis of C3VD in both pre and post-TAVR, proper diagnostic methods are still lacking because the fluid-dynamics methods that can be used as engines of new diagnostic tools are not well developed yet. Despite remarkable advances in medical imaging, imaging on its own is not enough to quantify the blood flow effectively. Moreover, understanding of C3VD in both pre and post-TAVR and its progression has been hindered by the absence of a proper non-invasive tool for the assessment of the cardiovascular function. To enable the development of new non-invasive diagnostic methods, we developed an innovative image-based patient-specific computational fluid dynamics framework for patients with C3VD who undergo TAVR to quantify metrics of: (1) global circulatory function; (2) global cardiac function as well as (3) local cardiac fluid dynamics. This framework is based on an innovative non-invasive Doppler-based patient-specific lumped-parameter algorithm and a 3-D strongly-coupled fluid-solid interaction. We validated the framework against clinical cardiac catheterization and Doppler echocardiographic measurements and demonstrated its diagnostic utility by providing novel analyses and interpretations of clinical data in eleven C3VD patients in pre and post-TAVR status. Our findings position this framework as a promising new non-invasive diagnostic tool that can provide blood flow metrics while posing no risk to the patient. The diagnostic information, that the framework can provide, is vitally needed to improve clinical outcomes, to assess patient risk and to plan treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Multimodality imaging in valvular heart disease: how to use state-of-the-art technology in daily practice.
- Author
-
Reid, Anna, Blanke, Philipp, Bax, Jeroen J, and Leipsic, Jonathon
- Subjects
HEART valve diseases ,ECHOCARDIOGRAPHY ,CARDIAC imaging ,VASCULAR diseases ,HEART diseases - Abstract
Our understanding of the complexities of valvular heart disease (VHD) has evolved in recent years, primarily because of the increased use of multimodality imaging (MMI). Whilst echocardiography remains the primary imaging technique, the contemporary evaluation of patients with VHD requires comprehensive analysis of the mechanism of valvular dysfunction, accurate quantification of severity, and active exclusion extravalvular consequences. Furthermore, advances in surgical and percutaneous therapies have driven the need for meticulous multimodality imaging to aid in patient and procedural selection. Fundamental decision-making regarding whom, when, and how to treat patients with VHD has become more complex. There has been rapid technological advancement in MMI; many techniques are now available in routine clinical practice, and their integration into has the potential to truly individualize management strategies. This review provides an overview of the current evidence for the use of MMI in VHD, and how various techniques within each modality can be used practically to answer clinical conundrums. Open in new tab Download slide Open in new tab Download slide [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Annular versus supra-annular sizing for transcatheter aortic valve replacement in bicuspid aortic valve disease.
- Author
-
Weir-McCall, Jonathan R., Attinger-Toller, Adrian, Blanke, Philipp, Perlman, Gidon Y., Sellers, Stephanie L., Wood, David, Webb, John G., and Leipsic, Jonathon
- Abstract
CT measurement of supra-annular area (SA) has been proposed as an alternative to annular area (AA) for sizing of trancatheter valves in biscuspid aortic valves (BAV). This study examines the reproducibility of SA and AA measurements and their potential impact on downstream transcatheter heart valve sizing and clinical outcomes. 44 consecutive patients (mean age: 73 ± 15 years, 57% male) undergoing CTA with subsequent SAPIEN 3 valve insertion for severe bicuspid aortic stenosis (AS) were included. AA was measured at the basal ring. SA was measured by generating a circle defined by the intercommisural distance. AA and SA were measured by 2 independent observers. Baseline characteristics, TAVR procedural data, and discharge echocardiography data were collected. The SA was significantly larger than the AA (562 ± 146mm2 vs. 518 ± 112mm2,p = 0.013). Interobserver agreement was high using both techniques (ICC AA = 0.98,p < 0.001; SA = 0.80,p < 0.001), but with narrower limits of agreement with AA measurements (mean difference (limits of agreement): AA = −3mm2 (22; 19), SA = −16mm2 (−92; 76)). AA-based device sizing demonstrated substantial agreement with final valve inserted (κ = 0.72,p < 0.001), while SA demonstrated fair agreement (κ = 0.40,p < 0.001). There was no difference in post TAVR gradients, paravalvular leakage or valve success between patients with concordant sizing between AA and SA, and those in whom SA would have suggested an alternate valve size. Supra-annular sizing is less reproducible than annular sizing, with no difference in procedural complication rates in patients in whom supra-annular sizing would have altered the device size used. These results suggest no role for supra-annular sizing in current clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy.
- Author
-
Makkar, Raj R, Blanke, Philipp, Leipsic, Jonathon, Thourani, Vinod, Chakravarty, Tarun, Brown, David, Trento, Alfredo, Guyton, Robert, Babaliaros, Vasilis, Williams, Mathew, Jilaihawi, Hasan, Kodali, Susheel, George, Isaac, Lu, Michael, McCabe, James M, Friedman, John, Smalling, Richard, Wong, Shing Chiu, Yazdani, Shahram, and Bhatt, Deepak L
- Subjects
- *
THROMBOSIS , *RESEARCH , *RESEARCH methodology , *AORTIC stenosis , *SURGICAL complications , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *PROSTHETIC heart valves , *COMPUTED tomography - Abstract
Background: Subclinical leaflet thrombosis, characterized by hypoattenuated leaflet thickening (HALT) and reduced leaflet motion observed on 4-dimensional computed tomography (CT), may represent a form of bioprosthetic valve dysfunction.Objectives: The U.S. Food and Drug Administration mandated CT studies to understand the natural history of this finding, differences between transcatheter and surgical valves, and its association with valve hemodynamics and clinical outcomes.Methods: The PARTNER 3 (The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients With Aortic Stenosis) CT substudy randomized 435 patients with low-surgical-risk aortic stenosis to undergo transcatheter aortic valve replacement (n = 221) or surgery (n = 214). Serial 4-dimensional CTs were performed at 30 days and 1 year and were analyzed independently by a core laboratory.Results: The incidence of HALT increased from 10% at 30 days to 24% at 1 year. Spontaneous resolution of 30-day HALT occurred in 54% of patients at 1 year, whereas new HALT appeared in 21% of patients at 1 year. HALT was more frequent in transcatheter versus surgical valves at 30 days (13% vs. 5%; p = 0.03), but not at 1 year (28% vs. 20%; p = 0.19). The presence of HALT did not significantly affect aortic valve mean gradients at 30 days or 1 year. Patients with HALT at both 30 days and 1 year, compared with those with no HALT at 30 days and 1 year, had significantly increased aortic valve gradients at 1 year (17.8 ± 2.2 mm Hg vs. 12.7. ± 0.3 mm Hg; p = 0.04).Conclusions: Subclinical leaflet thrombosis was more frequent in transcatheter compared with surgical valves at 30 days, but not at 1 year. The impact of HALT on thromboembolic complications and structural valve degeneration needs further assessment. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low Risk Sub-Study.
- Author
-
Blanke, Philipp, Leipsic, Jonathon A., Popma, Jeffrey J., Yakubov, Steven J., Deeb, G. Michael, Gada, Hemal, Mumtaz, Mubashir, Ramlawi, Basel, Kleiman, Neal S., Sorajja, Paul, Askew, Judah, Meduri, Christopher U., Kauten, James, Melnitchouk, Serguei, Inglessis, Ignacio, Huang, Jian, Boulware, Michael, Reardon, Michael J., Evolut Low Risk LTI Sub-study Investigators, and Evolut Low Risk LTI Substudy Investigators
- Subjects
- *
AORTIC valve , *AORTIC valve transplantation , *TOMOGRAPHY , *PAMPHLETS , *PERCUTANEOUS balloon valvuloplasty , *HEART valve prosthesis implantation , *PROSTHETICS , *ECHOCARDIOGRAPHY , *RESEARCH , *RESEARCH methodology , *AORTIC stenosis , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PROSTHETIC heart valves , *LONGITUDINAL method ,AORTIC valve surgery - Abstract
Background: Subclinical leaflet thrombosis has been reported after bioprosthetic aortic valve replacement, characterized using 4-dimensional computed tomographic imaging by hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RLM). The incidence and clinical implications of these findings remain unclear.Objectives: The aim of this study was to determine the frequency, predictors, and hemodynamic and clinical correlates of HALT and RLM after aortic bioprosthetic replacement.Methods: A prospective subset of patients not on oral anticoagulation enrolled in the Evolut Low Risk randomized trial underwent computed tomographic imaging 30 days and 1 year after transcatheter aortic valve replacement (TAVR) or surgery. The primary endpoint was the frequency of HALT at 30 days and 1 year, analyzed by an independent core laboratory using standardized definitions. Secondary endpoints included RLM, mean aortic gradient, and clinical events at 30 days and 1 year.Results: At 30 days, the frequency of HALT was 31 of 179 (17.3%) for TAVR and 23 of 139 (16.5%) for surgery; the frequency of RLM was 23 of 157 (14.6%) for TAVR and 19 of 133 (14.3%) for surgery. At 1 year, the frequency of HALT was 47 of 152 (30.9%) for TAVR and 33 of 116 (28.4%) for surgery; the frequency of RLM was 45 of 145 (31.0%) for TAVR and 30 of 111 (27.0%) for surgery. Aortic valve hemodynamic status was not influenced by the presence or severity of HALT or RLM at either time point. The rates of HALT and RLM were similar after the implantation of supra-annular, self-expanding transcatheter, or surgical bioprostheses.Conclusions: The presence of computed tomographic imaging abnormalities of aortic bioprostheses were frequent but dynamic in the first year after self-expanding transcatheter and surgical aortic valve replacement, but these findings did not correlate with aortic valve hemodynamic status after aortic valve replacement in patients at low risk for surgery. (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. 1-Year Outcomes of the CENTERA-EU Trial Assessing a Novel Self-Expanding Transcatheter Heart Valve.
- Author
-
Tchétché, Didier, Windecker, Stephan, Kasel, A. Markus, Schaefer, Ulrich, Worthley, Stephen, Linke, Axel, Abdel-Wahab, Mohamed, Le Breton, Herve, Søndergaard, Lars, Spence, Mark S., Petronio, Sonia, Baumgartner, Helmut, Hovorka, Tomas, Blanke, Philipp, and Reichenspurner, Hermann
- Abstract
Abstract Objectives The purpose of this study is to report the 1-year results of the CENTERA-EU trial. Background The CENTERA transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, California) is a low-profile (14-F eSheath compatible), self-expanding nitinol valve, with a motorized delivery system allowing for repositionability. The 30-day results of the CENTERA-EU trial demonstrated the short-term safety and effectiveness of the valve. Methods Implantations were completed in 23 centers in Europe, Australia, and New Zealand. Transfemoral access was used in all patients. Echocardiographic outcomes were adjudicated by a core laboratory at baseline, discharge, 30 days, 6 months, and 1 year. Major adverse clinical events were adjudicated by an independent clinical events committee. Results Between March 2015 and July 2016, 203 high-risk patients (age 82.7 ± 5.5 years, 67.5% women, 68.0% New York Heart Association functional class III or IV, Society of Thoracic Surgeons score 6.1 ± 4.2%) with severe, symptomatic aortic stenosis underwent transcatheter aortic valve replacement with the CENTERA THV. The primary endpoint of the study was 30-day mortality (1.0%). At 1 year, overall mortality was 9.1%, cardiovascular mortality was 4.6%, disabling stroke was 4.1%, new permanent pacemakers were implanted in 6.5% of patients at risk, and cardiac-related rehospitalization was 6.8%. Hemodynamic parameters were stable at 1 year, with a mean aortic valve gradient of 8.1 ± 4.7 mm Hg, a mean effective orifice area of 1.7 ± 0.42 cm
2 , and no incidences of severe or moderate aortic regurgitation. Conclusions The CENTERA-EU trial demonstrated mid-term safety and effectiveness of the CENTERA THV, with low mortality, sustained improvements in hemodynamic performances, and low incidence of permanent pacemaker implantations in high-risk patients with symptomatic aortic stenosis. (Safety and Performance of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560) Central Illustration [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
18. The Effect of Post-Dilatation on Outcomes in the PARTNER 2 SAPIEN 3 Registry.
- Author
-
Hahn, Rebecca T., Pibarot, Philippe, Leipsic, Jonathon, Blanke, Philipp, Douglas, Pamela S., Weissman, Neil J., Kapadia, Samir, Thourani, Vinod H., Herrmann, Howard C., Nazif, Tamim, McAndrew, Thomas, Webb, John G., Leon, Martin B., and Kodali, Susheel
- Abstract
Objectives The purpose of this study was to understand the effects of balloon post-dilatation on outcomes following transcatheter aortic valve replacement with the SAPIEN 3 valve. Background Hemodynamics and outcomes with balloon post-dilatation for the SAPIEN 3 valve have not been previously reported. Methods The effects of balloon post-dilatation (BPD) in 1,661 intermediate (S3i cohort) and high surgical risk (S3HR cohort) patients with aortic stenosis enrolled in the PARTNER (Placement of Aortic Transcatheter Valves) 2, SAPIEN 3 observational study on outcomes, as well as procedural complications, were assessed. Results 208 of 1,661 patients (12.5%) had BPD during the initial transcatheter aortic valve replacement. Baseline characteristics were similar except BPD had higher STS score (p < 0.001), significantly less % oversizing (p = 0.004), significantly more ≥moderate left ventricular outflow tract calcification (p = 0.005), and severe annular calcification (p = 0.006). BPD patients had no increase in permanent pacemaker, annular rupture, or valve embolization. Following transcatheter aortic valve replacement, BPD patients had significantly larger aortic valve area (1.72 ± 0.41 cm 2 vs. 1.66 ± 0.37 cm 2 ; p = 0.04) with no significant difference in prosthesis–patient mismatch (p = 0.08) or transvalvular aortic regurgitation (p = 0.65), but significantly more paravalvular regurgitation (p < 0.01). There was no significant difference in 30-day or 1-year outcomes of all-cause death (p = 0.65 to 0.76) or stroke (p = 0.28 to 0.72). However, at 1 year, there was a significantly higher incidence of minor stroke in BPD patients (p = 0.02). Adjusting for baseline differences, including calcium burden, minor strokes were no longer significantly different between the BPD and NoBPD groups (p = 0.21). Conclusions BPD is performed more frequently in patients with lower % oversizing and greater calcium burden. BPD is not associated with procedural complications or an increase in 1-year adverse events of death, rehospitalization, or stroke. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Computed Tomography–Based Oversizing Degrees and Incidence of Paravalvular Regurgitation of a New Generation Transcatheter Heart Valve.
- Author
-
Blanke, Philipp, Pibarot, Philippe, Hahn, Rebecca, Weissman, Neil, Kodali, Susheel, Thourani, Vinod, Parvataneni, Rupa, Dvir, Danny, Naoum, Christopher, Nørgaard, Bjarne L., Douglas, Pamela, Jaber, Wael, Khalique, Omar K., Jilaihawi, Hasan, Mack, Michael, Smith, Craig, Leon, Martin, Webb, John, and Leipsic, Jonathon
- Abstract
Objectives The aim of the study was to investigate the influence of the extent of computed tomography (CT)–based area and perimeter oversizing on the incidence and severity of paravalvular aortic regurgitation (PAR) for the Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, California) device, using CT data and echocardiographic outcome data of the PARTNER II (Placement of AoRTic TraNscathetER Valves Trial II) SAPIEN 3 intermediate-risk cohort. Background Transcatheter heart valve (THV) sizing algorithms are device specific, requiring refinements for new valve designs. Methods A total of 835 intermediate-risk patients with severe, symptomatic aortic stenosis enrolled in a multicenter, nonrandomized registry at 57 sites in the United States and Canada with available systolic CT data and echocardiographic follow-up were included in this analysis. THV size selection was primarily CT guided based on annular area. Area-based and perimeter-based oversizing was calculated using systolic annular CT dimensions and nominal dimensions of the implanted THV size. PAR was assessed at 30 days according to a 5-class scheme. Results Mean oversizing by area was 7.7 ± 9.4% and mean oversizing by perimeter was 1.7 ± 4.4%. An inverse proportional relationship between degree of oversizing and frequency and severity of PAR was observed for both area and perimeter oversizing. Perimeter and area oversizing confer similar predictive capacity in regard to the occurrence of PAR after THV implantation (area under the curve: 0.78 [95% confidence interval: 0.70 to 0.85] vs. area under the curve: 0.78 [95% confidence interval: 0.72 to 0.85]; p < 0.0001). No aortic root ruptures were observed. Conclusions For the SAPIEN 3 THV, the frequency and extent of PAR is inversely related to the degree of oversizing with acceptable rates of PAR being achieved at lower degrees of oversizing. Perimeter and area oversizing confer similar predictive capacity in regard to the occurrence of PAR after implantation of the SAPIEN 3 THV. Therefore, the SAPIEN 3 THV may offer the opportunity to reduce the risk of annular rupture associated with more significant degrees of oversizing in borderline annular anatomy. (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves [PARTNER II]; NCT01314313 ) [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Trials Testing the Value of Imaging Use in Valve Disease and in Transcatheter Valvular Interventions.
- Author
-
Leipsic, Jonathon, Bax, Jeroen J., Webb, John G., Martin, Randolph, and Blanke, Philipp
- Abstract
The role of imaging in the diagnosis of valvular heart disease is well established through years of investigation and validation. However, the role of imaging in guiding the treatment decision-making for valvular heart disease is less well established, and there is a striking paucity of randomized trial data to help inform these decisions. Given this relative absence of randomized trial data, the present article highlights some of the most important knowledge gaps and defines meaningful opportunities for the field to help advance the care of patients with valvular heart disease in a cost-effective fashion. (The PARTNER 3-Trial: The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [P3]; NCT02675114 ; Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283 ) [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Computed tomography assessment for transcatheter aortic valve in valve implantation: The vancouver approach to predict anatomical risk for coronary obstruction and other considerations.
- Author
-
Blanke, Philipp, Soon, Jeanette, Dvir, Danny, Park, Jong K., Naoum, Christopher, Kueh, Shaw-Hua, Wood, David A., Norgaard, Bjarne L., Selvakumar, Kapilan, Ye, Jian, Cheung, Anson, Webb, John G., and Leipsic, Jonathon
- Abstract
Valve-in-valve implantation of a transcatheter heart valve into a failed bioprosthetic heart valve has emerged as a treatment alternative to repeat conventional surgery. This requires careful pre-procedural assessment using non-invasive imaging to identify patients at risk for procedure related adverse events, such as ostial coronary occlusion. Herein we report how to comprehensively assess aortic root anatomy using computed tomography prior to transcatheter valve implantation for failed bioprosthetic aortic valves. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Bicuspid Aortic Valve Stenosis: Favorable Early Outcomes With a Next-Generation Transcatheter Heart Valve in a Multicenter Study.
- Author
-
Perlman, Gidon Y., Blanke, Philipp, Dvir, Danny, Pache, Gregor, Modine, Thomas, Barbanti, Marco, Holy, Erik W., Treede, Hendrik, Ruile, Philipp, Neumann, Franz-Josef, Gandolfo, Caterina, Saia, Francesco, Tamburino, Corrado, Mak, George, Thompson, Christopher, Wood, David, Leipsic, Jonathon, and Webb, John G.
- Abstract
Objectives This study evaluated the results of transcatheter aortic valve replacement (TAVR) in bicuspid aortic stenosis (AS) using a new-generation TAVR device. Background A bicuspid AS is often considered a relative contraindication to TAVR. Although initial reports have demonstrated feasibility using early-generation devices, outcomes have not matched those seen with tricuspid AS. Paravalvular aortic regurgitation (AR) has been particularly problematic. Methods We collected baseline characteristics, procedural data, and 30-day clinical follow-up findings from 8 centers in Europe and Canada that had performed TAVR in bicuspid AS using the SAPIEN 3 valve. Results 51 patients underwent TAVR using the SAPIEN 3 valve. Patient mean age was 76.2 ± 9.3 years and the Society of Thoracic Surgeons predicted risk of mortality scores were 5.2 ± 3.7%. Bicuspid valve types were: type 0, 11.8%; type 1, 82.3%; and type 2, 1.9%. There were no cases of valve embolization or need for a second valve. Post-dilation was performed in 7.8%. The mean aortic gradient decreased from 49.4 ± 16.0 mm Hg to 11.2 ± 4.7 mm Hg. Post-implantation AR was none/trivial in 63% and mild in 37%. There were no cases of moderate or severe AR. At 30-day follow-up, there were 2 deaths (3.9%), 2 major vascular complications, and 12 patients (23.5%) required pacemaker implantation. Conclusions TAVR in bicuspid AS using a new-generation device was feasible and effective with favorable valve performance and no cases of moderate or severe AR. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Clinical Outcomes and Imaging Findings in Women Undergoing TAVR.
- Author
-
Naoum, Christopher, Blanke, Philipp, Dvir, Danny, Pibarot, Philippe, Humphries, Karin, Webb, John, and Leipsic, Jonathon
- Abstract
Transcatheter aortic valve replacement (TAVR) has become the standard of care for patients with hemodynamically severe aortic stenosis who are symptomatic but deemed too high risk for surgery. Recent reports suggest that sex differences exist in outcomes following TAVR and in the diagnostic imaging evaluation of patients being considered for TAVR. In this review, the authors explore the differences between men and women in baseline characteristics and outcomes following TAVR, as well as sex differences in the imaging findings of severe aortic stenosis (AS) including the diagnostic challenges in the hemodynamic assessment of severe AS in elderly women, differences in aortic valvular calcification and in the associated myocardial response to severe AS. Additionally, sex differences in imaging findings as they relate to post-TAVR complications including coronary obstruction, annular rupture and prosthesis–patient mismatch are also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. In-hospital resource utilization in surgical and transcatheter aortic valve replacement.
- Author
-
Reinöhl, Jochen, Kaier, Klaus, Gutmann, Anja, Sorg, Stefan, von zur Mühlen, Constantin, Siepe, Matthias, Baumbach, Hardy, Moser, Martin, Geibel, Annette, Zirlik, Andreas, Blanke, Philipp, Vach, Werner, Beyersdorf, Friedhelm, Bode, Christoph, and Zehender, Manfred
- Subjects
AORTIC stenosis treatment ,HEART valve prosthesis implantation ,MEDICAL economics ,INTENSIVE care units ,LENGTH of stay in hospitals ,CLINICAL trials ,LONGITUDINAL method ,AORTIC stenosis ,ARTIFICIAL respiration ,COMPARATIVE studies ,PROSTHETIC heart valves ,HOSPITAL charges ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,ECONOMICS - Abstract
Background: Little is known about preoperative predictors of resource utilization in the treatment of high-risk patients with severe symptomatic aortic valve stenosis. We report results from the prospective, medical-economic "TAVI Calculation of Costs Trial".Methods: In-hospital resource utilization was evaluated in 110 elderly patients (age ≥ 75 years) treated either with transfemoral (TF) or transapical (TA) transcatheter aortic valve implantation (TAVI, N = 83), or surgical aortic valve replacement (AVR, N = 27). Overall, 22 patient-specific baseline parameters were tested for within-group prediction of resource use.Results: Baseline characteristics differed between groups and reflected the non-randomized, real-world allocation of treatment options. Overall procedural times were shortest for TAVI, intensive care unit (ICU) length of stay (LoS) was lowest for AVR. Length of total hospitalization since procedure (THsP) was lowest for TF-TAVI; 13.4 ± 11.4 days as compared to 15.7 ± 10.5 and 21.2 ± 15.4 days for AVR and TA-TAVI, respectively. For TAVI and AVR, EuroScore I remained the main predictor for prolonged THsP (p <0.01). Within the TAVI group, multivariate regression analyses showed that TA-TAVI was associated with a substantial increase in THsP (55 to 61 %, p <0.01). Additionally, preoperative aortic valve area (AVA) was identified as an independent predictor of prolonged THsP in TAVI patients, irrespective of risk scores (p <0.05).Conclusions: Our results demonstrate significant heterogeneity in patients baseline characteristics dependent on treatment and corresponding differences in resource utilization. Prolonged ThsP is not only predicted by risk scores but also by baseline AVA, which might be useful in stratifying TAVI patients.Trial Registration: German Clinical Trial Register Nr. DRKS00000797. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
25. Multidetector CT predictors of prosthesis–patient mismatch in transcatheter aortic valve replacement.
- Author
-
Freeman, Melanie, Webb, John G., Willson, Alexander B., Wheeler, Miriam, Blanke, Philipp, Moss, Robert R., Thompson, Christopher R., Munt, Brad, Norgaard, Bjarne L., Yang, Tae-Hyun, Min, James K., Poulsen, Steen, Hansson, Nicolaj C., Binder, Ronald K., Toggweiler, Stefan, Hague, Cameron, Wood, David A., Pibarot, Philippe, and Leipsic, Jonathon
- Abstract
Abstract: Background: Prosthesis–patient mismatch (PPM) is a predictor of mortality after aortic valve replacement (AVR). Objective: We examined whether accurate 3-dimensional annular sizing with multidetector CT (MDCT) is predictive of PPM after transcatheter AVR (TAVR). Methods: One hundred twenty-eight patients underwent MDCT then TAVR. Moderate PPM was defined as an indexed effective orifice area ≤0.85 cm
2 /m2 and severe ≤0.65 cm2 /m2 . MDCT annular measurements (area, short and long axis) were compared with the size of the selected transcatheter heart valve (THV) to obtain (1) the difference between prosthesis size and CT-measured mean annular diameter and (2) the percentage of undersizing or oversizing (calculated as 100 × [MDCT annular area – THV nominal area]/THV nominal area). In addition, the MDCT annular area was indexed to body surface area. These measures were evaluated as potential PPM predictors. Results: We found that 42.2% of patients had moderate PPM and 9.4% had severe PPM. Procedural characteristics and in-hospital outcomes were similar between patients with or without PPM. THV undersizing of the mean aortic annulus diameter was not predictive of PPM (odds ratio [OR], 0.84; 95% CI, 0.65–1.07; P = .16; area under the receiver-operating characteristic curve [AUC], 0.58). THV undersizing of annular area was not predictive of PPM (OR, 0.96; 95% CI, 0.80–1.16; P = .69; AUC, 0.52). Indexed MDCT annular area was, however, predictive of PPM (OR, 0.24; 95% CI, 0.10–0.59; P < .001; AUC, 0.66). Conclusions: PPM is frequent after TAVR. Appropriate annular oversizing does not reduce the rate or severity of PPM. Patient annulus size mismatch, identified by indexed MDCT annular area, is a significant predictor of PPM. [Copyright &y& Elsevier]- Published
- 2013
- Full Text
- View/download PDF
26. Prosthesis Oversizing in Balloon-Expandable Transcatheter Aortic Valve Implantation Is Associated With Contained Rupture of the Aortic Root.
- Author
-
Blanke, Philipp, Reinöhl, Jochen, Schlensak, Christian, Siepe, Matthias, Pache, Gregor, Euringer, Wulf, Geibel-Zehender, Annette, Bode, Christopher, Langer, Mathias, Beyersdorf, Friedhelm, and Zehender, Manfred
- Subjects
PROSTHETICS ,AORTIC stenosis ,TOMOGRAPHY ,STENOSIS ,FALSE aneurysms - Abstract
The article discusses a study on the association between prosthesis oversizing in balloon-expandable transcatheter aortic valve implantation (TAVI) and contained rupture of the aortic root. It shows that patients with contained rupture have higher rate of increased calculated average annulus diameter (CAAD). It also cites the possibility that the use of multislice computed tomography (MSCT)-based assessment of aortic annulus dimension may reduce the incidence of prosthesis oversizing.
- Published
- 2012
- Full Text
- View/download PDF
27. Preoperative Assessment of Aortic Annulus Dimensions: Comparison of Noninvasive and Intraoperative Measurement.
- Author
-
Dashkevich, Alexey, Blanke, Philipp, Siepe, Matthias, Pache, Gregor, Langer, Mathias, Schlensak, Christian, and Beyersdorf, Friedhelm
- Subjects
AORTIC valve surgery ,AORTIC stenosis ,TOMOGRAPHY ,TRANSPLANTATION of organs, tissues, etc. ,TRANSESOPHAGEAL echocardiography ,CATHETERIZATION ,DIAGNOSTIC imaging - Abstract
Background: Preoperative assessment of aortic annulus diameter is crucial for valve sizing in patients scheduled for transcatheter aortic valve replacement. Computed tomographic (CT) measurements of the aortic annulus are not standardized and may yield different results depending on view due to its elliptic shape. The purpose of this study was to compare the measurement of the aortic annulus during surgery in patients undergoing conventional aortic valve replacement with noninvasive methods. Methods: In 33 patients with aortic valve stenosis (18 males, mean age 77.2 ± 7.9), aortic annulus diameter was measured with cardiac CT and TEE (transesophageal echocardiography) prior to open aortic valve replacement. In CT, aortic annulus diameter was assessed as the calculated average diameter of luminal area at the level of basal attachments of the leaflets by means of planimetry. Operative measurements were performed with a Hegar dilator. A Pearson analysis was applied to test for degree of correlation. Results: Calculated average diameter by CT correlated significantly with intraoperative measurements (r = 0.923, p < 0.001) and with the size of implanted valve (r = 0.867, p < 0.001), while correlation of TEE and intraoperative measurements was weak (r = 0.523, p = 0.002). The TEE tends to underestimate the dimensions of aortic annulus. Conclusions: The CT-measured aortic annulus diameter, assessed as the calculated average diameter of planimetric annulus area, seems to provide adequate dimensions similar to operative measurements with a Hegar dilator. This approach may minimize the dependency of single-view CT measurement on the elliptic shape of the aortic annulus and appears to be a feasible alternative for aortic annulus assessment in terms of candidates'' selection for transcatheter aortic valve replacement. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
28. Outcome of Flow-Gradient Patterns of Aortic Stenosis After Aortic Valve Replacement: An Analysis of the PARTNER 2 Trial and Registry.
- Author
-
Salaun, Erwan, Clavel, Marie-Annick, Hahn, Rebecca T., Jaber, Wael A., Asch, Federico M., Rodriguez, Leonardo, Weissman, Neil J., Gertz, Zachary M., Herrmann, Howard C., Dahou, Abdellaziz, Annabi, Mohamed-Salah, Toubal, Oumhani, Bernier, Mathieu, Beaudoin, Jonathan, Leipsic, Jonathon, Blanke, Philipp, Ridard, Carine, Ong, Géraldine, Rodés-Cabau, Josep, and Webb, John G.
- Abstract
Supplemental Digital Content is available in the text. Background: Although aortic valve replacement is associated with a major benefit in high-gradient (HG) severe aortic stenosis (AS), the results in low-gradient (LG, mean gradient <40 mm Hg) AS are conflicting. LG severe AS may be subdivided in classical low-flow (left ventricular ejection fraction <50%) and LG (CLF-LG); paradoxical low-flow (left ventricular ejection fraction ≥50% but stroke volume index <35 mL/m
2 ) and LG; and normal-flow (left ventricular ejection fraction ≥50% and stroke volume index ≥35 mL/m2 ) and LG. The primary objective is to determine in the PARTNER 2 trial (The Placement of Aortic Transcatheter Valves) and registry the outcomes after aortic valve replacement of the 4 flow-gradient groups. Methods: A total of 3511 patients from the PARTNER 2 Cohort A randomized trial (n=1910) and SAPIEN 3 registry (n=1601) were included. The flow-gradient pattern was determined at baseline transthoracic echocardiography and classified as follows: (1) HG; (2) CLF-LG; (3) paradoxical low-flow-LG; and (4) normal-flow-LG. The primary end point for this analysis was the composite of (1) death; (2) rehospitalization for heart failure symptoms and valve prosthesis complication; or (3) stroke. Results: The distribution was HG, 2229 patients (63.5%); CLF-LG, 689 patients (19.6%); paradoxical low-flow-LG, 247 patients (7.0%); and normal-flow-LG, 346 patients (9.9%). The 2-year rate of primary end point was higher in CLF-LG (38.8%) versus HG: 31.8% (P =0.002) and normal-flow-LG: 32.1% (P =0.05) but was not statistically different from paradoxical low-flow-LG: 33.6% (P =0.18). There was no significant difference in the 2-year rates of clinical events between transcatheter aortic valve replacement versus surgical aortic valve replacement in the whole cohort and within each flow-gradient group. Conclusions: The LG AS pattern was highly prevalent (36.5%) in the PARTNER 2 trial and registry. CLF-LG was the most common pattern of LG AS and was associated with higher rates of death, rehospitalization, or stroke at 2 years compared with the HG group. Clinical outcomes were as good in the LG AS groups with preserved left ventricular ejection fraction compared with the HG group. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
29. ACR Appropriateness Criteria® Imaging for Transcatheter Aortic Valve Replacement.
- Author
-
Leipsic, Jonathon A., Blanke, Philipp, Hanley, Michael, Batlle, Juan C., Bolen, Michael A., Brown, Richard K.J., Desjardins, Benoit, Eberhardt, Robert T., Gornik, Heather L., Hurwitz, Lynne M., Maniar, Hersh, Patel, Himanshu J., Sheybani, Elizabeth F., Steigner, Michael L., Verma, Nupur, Abbara, Suhny, Rybicki, Frank J., Kirsch, Jacobo, Dill, Karin E., and Expert Panel on Cardiac Imaging and Vascular Imaging:
- Abstract
Aortic stenosis is a common valvular condition with increasing prevalence in aging populations. When severe and symptomatic, the downstream prognosis is poor without surgical or transcatheter aortic valve replacement. Transcatheter aortic valve replacement is now considered a viable alternative to surgical aortic valve replacement in patients considered high and intermediate risk for surgery. Pre-intervention imaging with echocardiography and CT are essential for procedure planning and device selection to help optimize clinical outcomes with MR angiography playing largely a complementary role. Modern 3-D cross-sectional imaging has consistently shown to help reduce procedural complications from vascular access injury to paravalvular regurgitation and coronary obstruction. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Towards a non-invasive computational diagnostic framework for personalized cardiology of transcatheter aortic valve replacement in interactions with complex valvular, ventricular and vascular disease.
- Author
-
Khodaei, Seyedvahid, Sadeghi, Reza, Blanke, Philipp, Leipsic, Jonathon, Emadi, Ali, and Keshavarz-Motamed, Zahra
- Subjects
- *
HEART valve prosthesis implantation , *VASCULAR diseases , *FLUID dynamics , *CARDIOVASCULAR diseases , *VASCULAR catheters , *AORTIC stenosis , *HEART - Abstract
• We developed a diagnostic framework for patients with transcatheter aortic valve. • Diagnostic framework uses a Doppler-based patient-specific lumped-parameter model. • Diagnostic framework uses a 3-D strongly-coupled fluid structure interaction model. • Diagnostic framework quantifies local and global hemodynamics. • Diagnostic framework provides a platform for testing the intervention scenarios. Aortic stenosis is an acute and chronic cardiovascular disease that often coexists with other complex valvular, ventricular and vascular diseases (C3VD). Transcatheter aortic valve replacement is an emerging less invasive intervention for patients with aortic stenosis. Although hemodynamics quantification is critical for accurate and early diagnosis of aortic stenosis and C3VD, proper diagnostic methods for these diseases are still lacking because fluid-dynamics methods, that can be used as engines of new diagnostic tools, are not well developed yet. As the heart resides in a sophisticated vascular network which imposes a load on the heart, effective diagnosis requires quantifications of the global hemodynamics (metrics of circulatory function and metrics of cardiac function), and of the local hemodynamics (cardiac fluid dynamics). To enable the development of new non-invasive diagnostic methods that can quantify local and global hemodynamics, we developed an innovative computational-mechanics and imaging-based framework that only needs patient data routinely and non-invasively measured in clinics. We not only validated the framework against clinical cardiac catheterization and Doppler echocardiographic measurements but also, we demonstrated its diagnostic utility in providing novel analyses and interpretations of clinical data. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk.
- Author
-
Leon, Martin B., Mack, Michael J., Hahn, Rebecca T., Thourani, Vinod H., Makkar, Raj, Kodali, Susheel K., Alu, Maria C., Madhavan, Mahesh V., Chau, Katherine H., Russo, Mark, Kapadia, Samir R., Malaisrie, S. Chris, Cohen, David J., Blanke, Philipp, Leipsic, Jonathon A., Williams, Mathew R., McCabe, James M., Brown, David L., Babaliaros, Vasilis, and Goldman, Scott
- Subjects
- *
HEART valve prosthesis implantation , *AORTIC stenosis , *HEART valves , *PERCUTANEOUS balloon valvuloplasty , *RESEARCH , *TIME , *RESEARCH methodology , *SURGICAL complications , *MEDICAL cooperation , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *PROSTHETIC heart valves , *LONGITUDINAL method - Abstract
Background: In low surgical risk patients with symptomatic severe aortic stenosis, the PARTNER 3 (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis) trial demonstrated superiority of transcatheter aortic valve replacement (TAVR) versus surgery for the primary endpoint of death, stroke, or re-hospitalization at 1 year.Objectives: This study determined both clinical and echocardiographic outcomes between 1 and 2 years in the PARTNER 3 trial.Methods: This study randomly assigned 1,000 patients (1:1) to transfemoral TAVR with the SAPIEN 3 valve versus surgery (mean Society of Thoracic Surgeons score: 1.9%; mean age: 73 years) with clinical and echocardiography follow-up at 30 days and at 1 and 2 years. This study assessed 2-year rates of the primary endpoint and several secondary endpoints (clinical, echocardiography, and quality-of-life measures) in this as-treated analysis.Results: Primary endpoint follow-up at 2 years was available in 96.5% of patients. The 2-year primary endpoint was significantly reduced after TAVR versus surgery (11.5% vs. 17.4%; hazard ratio: 0.63; 95% confidence interval: 0.45 to 0.88; p = 0.007). Differences in death and stroke favoring TAVR at 1 year were not statistically significant at 2 years (death: TAVR 2.4% vs. surgery 3.2%; p = 0.47; stroke: TAVR 2.4% vs. surgery 3.6%; p = 0.28). Valve thrombosis at 2 years was increased after TAVR (2.6%; 13 events) compared with surgery (0.7%; 3 events; p = 0.02). Disease-specific health status continued to be better after TAVR versus surgery through 2 years. Echocardiographic findings, including hemodynamic valve deterioration and bioprosthetic valve failure, were similar for TAVR and surgery at 2 years.Conclusions: At 2 years, the primary endpoint remained significantly lower with TAVR versus surgery, but initial differences in death and stroke favoring TAVR were diminished and patients who underwent TAVR had increased valve thrombosis. (Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis [PARTNER 3]; NCT02675114). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
32. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial.
- Author
-
Pibarot, Philippe, Ternacle, Julien, Jaber, Wael A, Salaun, Erwan, Dahou, Abdellaziz, Asch, Federico M, Weissman, Neil J, Rodriguez, Leonardo, Xu, Ke, Annabi, Mohamed-Salah, Guzzetti, Ezequiel, Beaudoin, Jonathan, Bernier, Mathieu, Leipsic, Jonathon, Blanke, Philipp, Clavel, Marie-Annick, Rogers, Erin, Alu, Maria C, Douglas, Pamela S, and Makkar, Raj
- Subjects
- *
PROSTHETIC heart valves , *RESEARCH funding , *AORTIC valve insufficiency , *COMPLICATIONS of prosthesis , *EQUIPMENT & supplies - Abstract
Background: It is unknown whether transcatheter valves will have similar durability as surgical bioprosthetic valves. Definitions of structural valve deterioration (SVD), based on valve related reintervention or death, underestimate the incidence of SVD.Objectives: This study sought to determine and compare the 5-year incidence of SVD, using new standardized definitions based on echocardiographic follow-up of valve function, in intermediate-risk patients with severe aortic stenosis given transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) in the PARTNER (Placement of Aortic Transcatheter Valves) 2A trial and registry.Methods: In the PARTNER 2A trial, patients were randomly assigned to receive either TAVR with the SAPIEN XT or SAVR, whereas in the SAPIEN 3 registry, patients were assigned to TAVR with the SAPIEN 3. The primary endpoint was the incidence of SVD, that is, the composite of SVD-related hemodynamic valve deterioration during echocardiographic follow-up and/or SVD-related bioprosthetic valve failure (BVF) at 5 years.Results: Compared with SAVR, the SAPIEN-XT TAVR cohort had a significantly higher 5-year exposure adjusted incidence rates (per 100 patient-years) of SVD (1.61 ± 0.24% vs. 0.63 ± 0.16%), SVD-related BVF (0.58 ± 0.14% vs. 0.12 ± 0.07%), and all-cause (structural or nonstructural) BVF (0.81 ± 0.16% vs. 0.27 ± 0.10%) (p ≤ 0.01 for all). The 5-year rates of SVD (0.68 ± 0.18% vs. 0.60 ± 0.17%; p = 0.71), SVD-related BVF (0.29 ± 0.12% vs. 0.14 ± 0.08%; p = 0.25), and all-cause BVF (0.60 ± 0.15% vs. 0.32 ± 0.11%; p = 0.32) in SAPIEN 3 TAVR were not significantly different to a propensity score matched SAVR cohort. The 5-year rates of SVD and SVD-related BVF were significantly lower in SAPIEN 3 versus SAPIEN XT TAVR matched cohorts.Conclusions: Compared with SAVR, the second-generation SAPIEN XT balloon-expandable valve has a higher 5-year rate of SVD, whereas the third-generation SAPIEN 3 has a rate of SVD that was not different from SAVR. (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII A [PARTNERII A]; NCT01314313; The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII - S3 Intermediate [PARTNERII S3i]; NCT03222128). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
33. Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry.
- Author
-
Webb, John G., Mack, Michael J., White, Jonathon M., Dvir, Danny, Blanke, Philipp, Herrmann, Howard C., Leipsic, Jonathon, Kodali, Susheel K., Makkar, Raj, Miller, D. Craig, Pibarot, Philippe, Pichard, Augusto, Satler, Lowell F., Svensson, Lars, Alu, Maria C., Suri, Rakesh M., and Leon, Martin B.
- Subjects
- *
REOPERATION , *SURGICAL complications , *DEATH rate , *ARTERIAL occlusions , *AORTIC valve , *COMPARATIVE studies , *PROSTHETIC heart valves , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *COMPLICATIONS of prosthesis , *QUALITY of life , *QUESTIONNAIRES , *RESEARCH , *EVALUATION research , *ACQUISITION of data ,AORTIC valve surgery - Abstract
Background: Early experience with transcatheter aortic valve replacement (TAVR) within failed bioprosthetic surgical aortic valves has shown that valve-in-valve (VIV) TAVR is a feasible therapeutic option with acceptable acute procedural results.Objectives: The authors examined 30-day and 1-year outcomes in a large cohort of high-risk patients undergoing VIV TAVR.Methods: Patients with symptomatic degeneration of surgical aortic bioprostheses at high risk (≥50% major morbidity or mortality) for reoperative surgery were prospectively enrolled in the multicenter PARTNER (Placement of Aortic Transcatheter Valves) 2 VIV trial and continued access registries.Results: Valve-in-valve procedures were performed in 365 patients (96 initial registry, 269 continued access patients). Mean age was 78.9 ± 10.2 years, and mean Society of Thoracic Surgeons score was 9.1 ± 4.7%. At 30 days, all-cause mortality was 2.7%, stroke was 2.7%, major vascular complication was 4.1%, conversion to surgery was 0.6%, coronary occlusion was 0.8%, and new pacemaker insertion was 1.9%. One-year all-cause mortality was 12.4%. Mortality fell from the initial registry to the subsequent continued access registry, both at 30 days (8.2% vs. 0.7%, respectively; p = 0.0001) and at 1 year (19.7% vs. 9.8%, respectively; p = 0.006). At 1 year, mean gradient was 17.6 mm Hg, and effective orifice area was 1.16 cm2, with greater than mild paravalvular regurgitation of 1.9%. Left ventricular ejection fraction increased (50.6% to 54.2%), and mass index decreased (135.7 to 117.6 g/m2), with reductions in both mitral (34.9% vs. 12.7%) and tricuspid (31.8% vs. 21.2%) moderate or severe regurgitation (all p < 0.0001). Kansas City Cardiomyopathy Questionnaire score increased (mean: 43.1 to 77.0) and 6-min walk test distance results increased (mean: 163.6 to 252.3 m; both p < 0.0001).Conclusions: In high-risk patients, TAVR for bioprosthetic aortic valve failure is associated with relatively low mortality and complication rates, improved hemodynamics, and excellent functional and quality-of-life outcomes at 1 year. (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves [PARTNER II]; NCT01314313). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
34. Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications.
- Author
-
Hansson, Nicolaj C., Grove, Erik L., Andersen, Henning R., Leipsic, Jonathon, Mathiassen, Ole N., Jensen, Jesper M., Jensen, Kaare T., Blanke, Philipp, Leetmaa, Tina, Tang, Mariann, Krusell, Lars R., Klaaborg, Kaj E., Christiansen, Evald H., Terp, Kim, Terkelsen, Christian J., Poulsen, Steen H., Webb, John, Bøtker, Hans Erik, and Nørgaard, Bjarne L.
- Subjects
- *
AORTIC valve diseases , *THROMBOSIS , *DISEASE incidence , *DISEASE susceptibility , *TRANSESOPHAGEAL echocardiography , *THROMBOSIS diagnosis , *AORTIC valve , *AORTIC stenosis , *PROSTHETIC heart valves , *LONGITUDINAL method , *PROGNOSIS , *RETROSPECTIVE studies , *SURGICAL complications , *MULTIDETECTOR computed tomography , *DIAGNOSIS ,AORTIC valve surgery - Abstract
Background: There are limited data on the incidence, clinical implications, and predisposing factors of transcatheter heart valve (THV) thrombosis following transcatheter aortic valve replacement (TAVR).Objectives: The authors assessed the incidence, potential predictors, and clinical implications of THV thrombosis as determined by contrast-enhanced multidetector computed tomography (MDCT) after TAVR.Methods: Among 460 consecutive patients who underwent TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) THV, 405 (88%) underwent MDCT in addition to transthoracic and transesophageal echocardiography 1 to 3 months post-TAVR. MDCT scans were evaluated for hypoattenuated leaflet thickening that indicated THV thrombosis.Results: MDCT verified THV thrombosis in 28 of 405 (7%) patients. A total of 23 patients had subclinical THV thrombosis, whereas 5 (18%) patients experienced clinically overt obstructive THV thrombosis. THV thrombosis risk did not differ among different generations of THVs (8% vs. 6%; p = 0.42). The risk of THV thrombosis in patients who did not receive warfarin was higher compared with patients who received warfarin (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.86 to 19.84). A larger THV was associated with an increased risk of THV thrombosis (p = 0.03). In multivariable analysis, a 29-mm THV (RR: 2.89; 95% CI: 1.44 to 5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68 to 17.7) independently predicted THV thrombosis. Treatment with warfarin effectively reverted THV thrombosis and normalized THV function in 85% of patients as documented by follow-up transesophageal echocardiography and MDCT.Conclusions: Incidence of THV thrombosis in this large study was 7%. A larger THV size may predispose to THV thrombosis, whereas treatment with warfarin appears to have a protective effect. Although often subclinical, THV thrombosis may have important clinical implications. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
35. Transcatheter Aortic Valve Replacement With Early- and New-Generation Devices in Bicuspid Aortic Valve Stenosis.
- Author
-
Yoon, Sung-Han, Lefèvre, Thierry, Ahn, Jung-Ming, Perlman, Gidon Y., Dvir, Danny, Latib, Azeem, Barbanti, Marco, Deuschl, Florian, De Backer, Ole, Blanke, Philipp, Modine, Thomas, Pache, Gregor, Neumann, Franz-Josef, Ruile, Philipp, Arai, Takahide, Ohno, Yohei, Kaneko, Hidehiro, Tay, Edgar, Schofer, Niklas, and Holy, Erik W.
- Subjects
- *
ARTERIAL stenosis treatment , *ARTERIAL stenosis , *AORTIC valve transplantation , *BICUSPIDS , *HEALTH outcome assessment , *PATIENTS , *SURGERY , *AORTIC valve abnormalities , *PROSTHETIC heart valves , *AORTIC stenosis , *COMPARATIVE studies , *HEART valve diseases , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *PRODUCT design , *EVALUATION research , *DISEASE complications , *EQUIPMENT & supplies ,AORTIC valve surgery - Abstract
Background: Few studies have evaluated the clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve stenosis (AS). Particularly, limited data exist comparing the results of TAVR with new-generation devices versus early-generation devices.Objectives: This study sought to evaluate the clinical outcomes of TAVR for bicuspid AS with early- and new-generation devices.Methods: The Bicuspid TAVR Registry is an international multicenter study enrolling consecutive patients with bicuspid AS undergoing TAVR between April 2005 and May 2015.Results: Of 301 patients, 199 patients (71.1%) were treated with early-generation devices (Sapien XT [Edwards Lifesciences Corporation, Irvine, California]: n = 87; CoreValve [Medtronic, Minneapolis, Minnesota]: n = 112) and 102 with new-generation devices (Sapien 3 [Edwards Lifesciences Corporation]: n = 91; Lotus [Boston Scientific Corporation, Marlborough, Massachusetts]: n = 11). The mean Society of Thoracic Surgeons score was 4.7 ± 5.2 without significant differences between groups (4.6 ± 5.1 vs. 4.9 ± 5.4; p = 0.57). Overall, all-cause mortality rates were 4.3% at 30 days and 14.4% at 1 year. Moderate or severe paravalvular leak was absent and significantly less frequent with new-generation compared to early-generation devices (0.0% vs. 8.5%; p = 0.002), which resulted in a higher device success rate (92.2% vs. 80.9%; p = 0.01). There were no differences between early- and new-generation devices in stroke (2.5% vs. 2.0%; p > 0.99), life-threatening bleeding (3.5% vs. 2.9%; p > 0.99), major vascular complication (4.5% vs. 2.9%; p = 0.76), stage 2 to 3 acute kidney injury (2.5% vs. 2.9%; p > 0.99), early safety endpoints (15.1% vs. 10.8%; p = 0.30), and 30-day all-cause mortality (4.5% vs. 3.9%; p > 0.99).Conclusions: The clinical outcomes of TAVR in patients with bicuspid AS were favorable. New-generation devices were associated with less paravalvular leak and, hence, a higher device success rate than early-generation devices. (The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry [Bicuspid TAVR]; NCT02394184). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
36. Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis
- Author
-
Jeroen J. Bax, Yigal Abramowitz, Hidehiro Kaneko, Fabian Nietlispach, Niklas Schofer, Thomas Modine, Omar K. Khalique, Tarun Chakravarty, Masao Takahashi, S. Chiu Wong, Ulrich Schaefer, Thierry Lefèvre, Erik W. Holy, Brian Whisenant, Seung-Jung Park, Smriti Saraf, Florian Deuschl, Emmanuel Teiger, Gidon Y. Perlman, Ole De Backer, Yohei Ohno, Christian Butter, Marco Barbanti, Rahul Sharma, Mohamed Abdel-Wahab, Franz-Josef Neumann, Philipp Blanke, Gerald Yong, Antonio Colombo, Hiroyuki Kawamori, Bernard Chevalier, Mamoo Nakamura, Hyo-Soo Kim, Johannes Ziegelmueller, William K.F. Kong, Susheel Kodali, Michael S. Lee, Shingo Kuwata, Sung Han Yoon, Buntaro Fujita, Luca Testa, Edgar Tay, Stephan Ensminger, Daisuke Sugiyama, Corrado Tamburino, Jonathon Leipsic, Hsien-Li Kao, Yoshio Maeno, John G. Webb, Victoria Delgado, David Hildick-Smith, Lars Søndergaard, Takahide Arai, Raj Makkar, Tobias Schmidt, Danny Dvir, Francesco Bedgoni, Azeem Latib, Philipp Ruile, Sabine Bleiziffer, Martin B. Leon, Gregor Pache, Yoon, Sung han, Bleiziffer, Sabine, De Backer, Ole, Delgado, Victoria, Arai, Takahide, Ziegelmueller, Johanne, Barbanti, Marco, Sharma, Rahul, Perlman, Gidon Y., Khalique, Omar K., Holy, Erik W., Saraf, Smriti, Deuschl, Florian, Fujita, Buntaro, Ruile, Philipp, Neumann, Franz josef, Pache, Gregor, Takahashi, Masao, Kaneko, Hidehiro, Schmidt, Tobia, Ohno, Yohei, Schofer, Nikla, Kong, William K. F., Tay, Edgar, Sugiyama, Daisuke, Kawamori, Hiroyuki, Maeno, Yoshio, Abramowitz, Yigal, Chakravarty, Tarun, Nakamura, Mamoo, Kuwata, Shingo, Yong, Gerald, Kao, Hsien li, Lee, Michael, Kim, Hyo soo, Modine, Thoma, Wong, S. Chiu, Bedgoni, Francesco, Testa, Luca, Teiger, Emmanuel, Butter, Christian, Ensminger, Stephan M., Schaefer, Ulrich, Dvir, Danny, Blanke, Philipp, Leipsic, Jonathon, Nietlispach, Fabian, Abdel wahab, Mohamed, Chevalier, Bernard, Tamburino, Corrado, Hildick smith, David, Whisenant, Brian K., Park, Seung jung, Colombo, Antonio, Latib, Azeem, Kodali, Susheel K., Bax, Jeroen J., Sã¸ndergaard, Lar, Webb, John G., Lefãvre, Thierry, Leon, Martin B., and Makkar, Raj
- Subjects
Aortic valve ,Male ,medicine.medical_treatment ,Heart Valve Diseases ,030204 cardiovascular system & hematology ,Global Health ,aortic stenosis ,bicuspid aortic valve ,transcatheter aortic valve implantation ,Aged ,Aortic Valve ,Aortic Valve Stenosis ,Female ,Humans ,Retrospective Studies ,Survival Rate ,Transcatheter Aortic Valve Replacement ,Treatment Outcome ,Tricuspid Valve ,Heart Valve Prosthesis ,Cardiology and Cardiovascular Medicine ,0302 clinical medicine ,Bicuspid aortic valve ,Bicuspid Aortic Valve Disease ,Valve replacement ,Retrospective Studie ,Heart Valve Diseases/surgery ,030212 general & internal medicine ,Survival Rate/trends ,Tricuspid valve ,Heart Valve Disease ,medicine.anatomical_structure ,Aortic valve stenosis ,Cardiology ,cardiovascular system ,Human ,Transcatheter Aortic Valve Replacement/methods ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Aortic Valve Stenosis/mortality ,Tricuspid Valve/abnormalities ,03 medical and health sciences ,Internal medicine ,medicine ,cardiovascular diseases ,Survival rate ,business.industry ,Aortic Valve/abnormalities ,Retrospective cohort study ,aortic stenosi ,medicine.disease ,Aortic Valve Stenosi ,Stenosis ,Heart Valve Prosthesi ,business - Abstract
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid aortic valve stenosis (AS).OBJECTIVES: This study sought to compare the procedural and clinical outcomes in patients with bicuspid versus tricuspid AS from the Bicuspid AS TAVR multicenter registry.METHODS: Outcomes of 561 patients with bicuspid AS and 4,546 patients with tricuspid AS were compared after propensity score matching, assembling 546 pairs of patients with similar baseline characteristics. Procedural and clinical outcomes were recorded according to Valve Academic Research Consortium-2 criteria.RESULTS: Compared with patients with tricuspid AS, patients with bicuspid AS had more frequent conversion to surgery (2.0% vs. 0.2%; p = 0.006) and a significantly lower device success rate (85.3% vs. 91.4%; p = 0.002). Early-generation devices were implanted in 320 patients with bicuspid and 321 patients with tricuspid AS, whereas new-generation devices were implanted in 226 and 225 patients with bicuspid and tricuspid AS, respectively. Within the group receiving early-generation devices, bicuspid AS had more frequent aortic root injury (4.5% vs. 0.0%; p = 0.015) when receiving the balloon-expanding device, and moderate-to-severe paravalvular leak (19.4% vs. 10.5%; p = 0.02) when receiving the self-expanding device. Among patients with new-generation devices, however, procedural results were comparable across different prostheses. The cumulative all-cause mortality rates at 2 years were comparable between bicuspid and tricuspid AS (17.2% vs. 19.4%; p = 0.28).CONCLUSIONS: Compared with tricuspid AS, TAVR in bicuspid AS was associated with a similar prognosis, but lower device success rate. Procedural differences were observed in patients treated with the early-generation devices, whereas no differences were observed with the new-generation devices.
- Published
- 2017
37. OUTCOMES OF THE DIFFERENT FLOW/GRADIENT PATTERNS OF AORTIC STENOSIS AFTER AORTIC VALVE REPLACEMENT: INSIGHTS FROM PARTNER 2A TRIAL.
- Author
-
Pibarot, Philippe, Gertz, Zachary, Herrmann, Howard, Hahn, Rebecca, Jaber, Wael, Rodriguez, Leonardo, Weissman, Neil, Leipsic, Jonathon, Blanke, Philipp, Webb, John, Zhang, Yiran, Clavel, Marie-Annick, Alu, Maria, Douglas, Pamela, Makkar, Raj, Miller, D. Craig, Lindman, Brian, Thourani, Vinod, and Leon, Martin
- Subjects
- *
AORTIC stenosis - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.